olanzapine
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Weight Gain
Conditions
Weight Gain
Trial Timeline
Mar 1, 2003 → Aug 1, 2005
NCT ID
NCT00191828About olanzapine
olanzapine is a approved stage product being developed by Eli Lilly for Weight Gain. The current trial status is completed. This product is registered under clinical trial identifier NCT00191828. Target conditions include Weight Gain.
What happened to similar drugs?
3 of 20 similar drugs in Weight Gain were approved
Approved (3) Terminated (1) Active (16)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00982020 | Approved | Completed |
| NCT00618748 | Phase 3 | Completed |
| NCT00568672 | Phase 3 | Withdrawn |
| NCT00510211 | Pre-clinical | Completed |
| NCT00290121 | Approved | Completed |
| NCT00275301 | Pre-clinical | Completed |
| NCT00259272 | Phase 3 | Completed |
| NCT00113594 | Phase 3 | Completed |
| NCT00191997 | Approved | Completed |
| NCT00088036 | Phase 3 | Completed |
| NCT00100776 | Approved | Completed |
| NCT00191828 | Approved | Completed |
| NCT00194064 | Phase 3 | Terminated |
| NCT00036088 | Approved | Completed |
| NCT00260962 | Phase 2 | Completed |
| NCT00182507 | Approved | Completed |
Competing Products
20 competing products in Weight Gain